Relay Therapeutics Inc. (RLAY): Price and Financial Metrics
RLAY Price/Volume Stats
| Current price | $8.59 | 52-week high | $24.40 |
| Prev. close | $8.81 | 52-week low | $8.36 |
| Day low | $8.36 | Volume | 1,053,800 |
| Day high | $8.71 | Avg. volume | 1,328,666 |
| 50-day MA | $10.84 | Dividend yield | N/A |
| 200-day MA | $14.09 | Market Cap | 1.05B |
RLAY Stock Price Chart Interactive Chart >
RLAY POWR Grades
- RLAY scores best on the Value dimension, with a Value rank ahead of 42.55% of US stocks.
- RLAY's strongest trending metric is Stability; it's been moving up over the last 179 days.
- RLAY's current lowest rank is in the Momentum metric (where it is better than 3.57% of US stocks).
RLAY Stock Summary
- Of note is the ratio of RELAY THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; merely 6.99% of US stocks have a lower such ratio.
- With a price/sales ratio of 1,166.88, RELAY THERAPEUTICS INC has a higher such ratio than 99.52% of stocks in our set.
- Revenue growth over the past 12 months for RELAY THERAPEUTICS INC comes in at -53.3%, a number that bests merely 4.82% of the US stocks we're tracking.
- Stocks that are quantitatively similar to RLAY, based on their financial statements, market capitalization, and price volatility, are KRTX, AUR, BBIO, INBX, and CLDX.
- RLAY's SEC filings can be seen here. And to visit RELAY THERAPEUTICS INC's official web site, go to relaytx.com.
RLAY Valuation Summary
- RLAY's price/sales ratio is 1166.9; this is 61315.79% higher than that of the median Healthcare stock.
- Over the past 39 months, RLAY's EV/EBIT ratio has gone up 28.6.
Below are key valuation metrics over time for RLAY.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RLAY | 2023-09-18 | 1166.9 | 1.4 | -3.2 | -2.9 |
| RLAY | 2023-09-15 | 1214.9 | 1.4 | -3.3 | -3.1 |
| RLAY | 2023-09-14 | 1246.0 | 1.4 | -3.4 | -3.1 |
| RLAY | 2023-09-13 | 1230.4 | 1.4 | -3.4 | -3.1 |
| RLAY | 2023-09-12 | 1278.3 | 1.5 | -3.5 | -3.2 |
| RLAY | 2023-09-11 | 1270.6 | 1.5 | -3.5 | -3.2 |
RLAY's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RLAY has a Quality Grade of C, ranking ahead of 49.22% of graded US stocks.
- RLAY's asset turnover comes in at 0.111 -- ranking 257th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows RLAY's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.111 | 1 | -0.620 |
| 2021-03-31 | 0.125 | 1 | -0.215 |
| 2020-12-31 | 0.146 | 1 | -0.191 |
RLAY Price Target
For more insight on analysts targets of RLAY, see our RLAY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $54.33 | Average Broker Recommendation | 1.36 (Strong Buy) |
Relay Therapeutics Inc. (RLAY) Company Bio
Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
Latest RLAY News From Around the Web
Below are the latest news stories about RELAY THERAPEUTICS INC that investors may wish to consider to help them evaluate RLAY as an investment opportunity.
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsCAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that data for RLY-4008 (lirafugratinib) in patients with advanced FGFR2-altered solid tumors outside of cholangiocarcinoma will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therap |
12 Best High Risk High Reward Stocks To Buy NowIn this piece, we will take a look at the 12 best high risk high reward stocks to buy now. If you want to skip our background on investing, then head on over to 5 Best High Risk High Reward Stocks To Buy Now. Investing is a risky endeavor, as is anything that involves the […] |
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue EstimatesRelay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -3.85% and 69.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate HighlightsInitiated dose expansion cohort for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Updated RLY-2608 600mg BID + fulvestrant data: interim clinical benefit rate of 86% (6 of 7 evaluable patients) & 1 of 5 patients with measurable disease achieved a partial response Clinical benefit, including partial responses, observed across PI3Kα mutations and dose levels Approximately $872 million in cash, cash equivalents and investments at end of Q2 2023, |
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2023 financial results and corporate highlights after the U.S. financial markets close on Tuesday, August 8, 2023. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company tran |
RLAY Price Returns
| 1-mo | -19.57% |
| 3-mo | -27.63% |
| 6-mo | -43.89% |
| 1-year | -61.18% |
| 3-year | -80.77% |
| 5-year | N/A |
| YTD | -42.50% |
| 2022 | -51.35% |
| 2021 | -26.11% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...